Pharma Marketletter articles from August 2005

Pharma Marketletter archives from August 2005

Zimbabwe's Datlabs allies with Ranbaxy.(Brief Article)
August 1, 2005... Datlabs, one of the largest pharmaceutical manufacturers in Zimbabwe and domestic market leader in supplying drugs to the public and private sector, says it gains its strong new product pipeline from South African parent firm Adcock Ingram, as...

Schering AG 1st-half profits leap 23%.
August 1, 2005... Schering AG, the world's largest producer of contraceptives and Germany's third biggest drugmaker, posted a strong set of results for the first half of 2005, with a 23% jump in net profits to 320.0 million euros ($385.7 million) and earnings...

Crucell loss rises.(Brief Article)
August 1, 2005... Netherlands-based biotechnology group Crucell NV has reported an 8% rise in first-half 2005 sales to 16.1 million euros (19.4 million), driven mainly by a strong increase in service fees, noted the firm's chief financial officer, Leonard...

Bangladesh's Beximco to raise L27M in UK.(Brief Article)
August 1, 2005... In an ambitious expansion scheme, leading Bangladeshi firm Beximco has unveiled plans to raise around L27.0 million ($47.2 million) through Global Depository Receipts on the UK stock market. The Beximco Pharmaceuticals division is to merge...

Sanofi-Pasteur starts on US flu vacc plant.(Brief Article)
August 1, 2005... Sanofi Pasteur, the biologicals unit of leading French drugmaker Sanofi-Aventis, says that it has begun work on the construction of a new $150.0 million, 145,000-square-foot manufacturing facility in Swiftwater, Pennsylvania, USA, to produce...

Novartis in talks for R&D center in China.(Brief Article)
August 1, 2005... The president of the Swiss major drugmaker Novartis, Daniel Vasella, has confirmed that the group is investigating a number of sites and is in talks with the Chinese authorities over the setting-up of a drugs R&D center. The latest discussions...

Merck KGaA 2nd-qtr as expected.
August 1, 2005... German drugmaker Merck KGaA saw second-quarter 2005 group turnover rise 8.6% to 1.48 billion euros ($1.78 billion), with operating profit up 14.9% at 202.9 million euros. Net profit after tax was down 30.8% on the like 2004 period, at 252.1...

bioMerieux sales up 4%.(Brief Article)
August 1, 2005... French biologicals and diagnostics group bioMerieux has reported first-half 2005 turnover of 475.0 million euros ($572.5 million), a rise of 4% on the like, 2004 period. Like-for-like sales were flat in the first quarter (up 0.2%) but rose...

Novartis completes Eon Labs acquisition.(Brief Article)
August 1, 2005... Leading Swiss drugmaker Novartis has completed its purchase of US generics firm Eon Labs announced earlier this year (Marketletter February 28), in a transaction valued at around 5.65 billion euros ($6.81 billion). Conclusion of the deal...

Litigation reserves bite into Schering-Plough's 2nd-qtr, but sales rise 18%.
August 1, 2005... US drug major Schering-Plough sustained a net loss of $48.0 million, or $0.05 a share, for the second quarter of 2005, which included $259.0 million in special charges primarily related to an increase in litigation reserves relating to...

Amgen sees whopping 38% net profit and 26% sales rises, beating all expectations.
August 1, 2005... Amgen, the world's largest biotechnology company, saw its share price surge 15% to $81.17 after it reported record-breaking and better-than-expected second-quarter 2005 results. The California, USA-based firm posted adjusted earnings per...

Pfizer to submit Sutent IND.(Brief Article)
August 1, 2005... Although Pfizer says it does not normally comment in advance on the expected timing of regulatory submissions, it ha ssued a statement to address recent analysts' comments regarding the regulatory filing of Suten (sunitinib malate) in the USA....

GSK debuts on-line program for patients with depression.(GlaxoSmithKline)(Brief Article)
August 1, 2005... In what the firm says is an effort to provide ongoing support for people with major depressive disorder (commonly referred to as depression), panic disorder and social anxiety disorder, UK drug major GlaxoSmithKline has announced the launch of...

Evotec in focused library deal with Almirall.(contracts)(Brief Article)
August 1, 2005... Germany's Evotec AG and Almirall Prodesfarma, the leading Spanish multinational drug company, have entered into a two-year library synthesis agreement worth around 2.5 million euros ($3.0 million). Applying leading skills in high-speed...

Adherex closes $8.5M placing.(Brief Article)
August 1, 2005... Adherex Technologies, a US biopharmaceutical company with a broad portfolio of oncology products under development, says that it has completed its previously-announced private placement offering of units for gross proceeds of $8.5 million in...

UK DoH tenders for 2M doses of flu vacc.(UK Department of Health )(Brief Article)
August 1, 2005... The UK Department of Health has invited manufacturers to tender for a contract to supply two million doses of H5N1 vaccine, as part of the work to prepare for and reduce the impact of a possible flu pandemic. This strategic stockpile could...

UPDATE: UK NICE fast-track of Herceptin welcomed.(Brief Article)
August 1, 2005... The UK government's decision to make an early referral of Genentech's Herceptin (trastuzumab), used in the treatment of early-stage breast cancer, to the National Institute for Health and Clinical Excellence in advance of its 12th-wave work...

France moves to monitor drugs post-marketing.(Brief Article)
August 1, 2005... France's health care products safety agency, the Afssaps, is to set up a new department to monitor drugs in the post-marketing authorization phase and maintain a check on information produced on them. The new department, to be headed by...

PhRMA preliminary OK for DTC voluntary guiding principles, but CU slams "placebo".(Pharmaceutical Research and Manufacturers of America )
August 1, 2005... The board of the Pharmaceutical Research and Manufacturers of America has given preliminary approval to a set of "guiding principles" on direct-to-consumer advertising of prescription medicines.E Some of the areas addressed by the guiding...

Florida sues generics firms over Medicaid "scam".(Brief Article)
August 1, 2005... The US state of Florida's Attorney General, Charlie Crist, has filed suit against three drugmakers, claiming they defrauded the Medicaid program at a cost to the state of $25.0 million. The suit alleges that Mylan Pharmaceuticals, Teva...

US IoM drug safety panel urged to seek federally-mandated clinical trial registry.(US Institute of Medicine's Committee)
August 1, 2005... The US Institute of Medicine's Committee on the Assessment of the US Drug Safety System (Marketletter June 20) has been urged to recommend a federal mandate of public registry for pharmaceutical clinical trials, as well as public disclosure of...

Private labs making steady inroads into US non-Rx pharma market.
August 1, 2005... Led by mass-merchandisers and wholesale clubs, private-label products continue to make a slow but steady push into the US non-prescription drug market. The overall share for store-brand over-the-counter medications increased to more than 20.0%...

Cancer drugs drive Rx success and claim marketing dollars.(Brief Article)
August 1, 2005... Cancer drugs, along with treatments for high cholesterol, ulcers and depression, have claimed their spot as key products in the pharmaceutical portfolio. As such, the marketing budgets that accompany their development and launch continue to...

Lilly swings to loss in 2nd qtr on settlement.
August 1, 2005... US drug major Eli Lilly saw its performance for the second quarter of 2005 swing to a loss, as a modest rise in sales was not enough to counter the impact of its legal settlement regarding its top-selling antipsychotic Zyprexa (olanzapine). ...

Lilly ICOS slashes loss.(Brief Article)
August 1, 2005... The Eli Lilly and ICOS joint venture Lilly ICOS saw its second-quarter 2005 net loss fall dramatically to $1.7 million versus $70.5 million for the year-ago period, as global sales of the erectile dysfunction drug Cialis (tadalafil) leapt 39%...

Tax charges slice Merck & Co's 2nd-qtr income.
August 1, 2005... New Jersey, USA-based drugmaker Merck & Co has reported a substantial drop in second-quarter 2005 earnings, primarily due to a tax charge hit of $640.0 million. The group saw its net income plummet to $720.6 million, or $0.33 per share, from...

Baxter's 2nd-qtr 2005 sales jump 8%.(Brief Article)
August 1, 2005... US health care group Baxter has posted an 8% rise in sales to $2.60 billion for the second quarter of 2005, helping to drive the company's income to $324.0 million, or $0.51 a share, from a loss of $169.0 million, or $0.28 per share, for the...

FDA accepts Spectrum's ANDA for cancer drug.
August 1, 2005... California, USA-based Spectrum Pharmaceuticals says that it has filed an Abbreviated New Drug Application with the US Food and Drug Administration for an undisclosed injectable anticancer drug. The company noted that it now has 11 ANDAs on file...

Alfacell sells RNase drug rights to NITD.(Novartis Institute for Tropical Diseases )(Brief Article)
August 1, 2005... New Jersey, USA-headquartered Alfacell Corp says it has signed a Material Transfer Agreement with the Singapore-based Novartis Institute for Tropical Diseases for the former's novel ribonuclease antiviral drug candidate, AC 03-636. The...

ChemGenex/Stragen sign deal for Ceflatonin.(Stragen Pharma )(Brief Article)
August 1, 2005... Australian cancer drug developer ChemGenex has signed a deal with Geneva, Switzerland-based Stragen Pharma for the development and commercialization of its anticancer product Ceflatonin (homoharringtonine), which is currently in Phase II...

Nabi starts Ph I trial of S aureus 336 vaccine.(Brief Article)
August 1, 2005... Nabi Biopharmaceuticals of the USA has initiated a double-blind, placebo-controlled Phase I study of its Staphylococcus aureus vaccine, which is being evaluated for the prevention of type 336 infections in at-risk patients, such as those...

BDSI's Emexine accepted for review.(BioDelivery Sciences International )(Brief Article)
August 1, 2005... US specialty biopharmaceutical group BioDelivery Sciences International says that the Food and Drug Administration has accepted its New Drug Application for Emezine, a formulation of the currently-approved nausea and vomiting agent...

Neuren/US Army expand brain drug deal.(Walter Reed Army Institute of Research)(Brief Article)
August 1, 2005... New Zealand's Neuren Pharmaceuticals says it has expanded its agreement with the Walter Reed Army Institute of Research, the leading medical research arm of the US Army, for the brain trauma drug NNZ-2566. According to the company, the...

FDA requests efficacy data for Entereg appro.
August 1, 2005... Adolor Corp of the USA and UK drug major GlaxoSmithKline say that the US Food and Drug Administration has issued an approvable letter in response to Adolor's New Drug Application for Entereg (alvimopan) capsules. The agent is in development for...

DOR BioPharma and Cambrex hit milestone.(Brief Article)
August 1, 2005... US groups DOR BioPharma and a subsidiary of Cambrex Corp have successfully attained the first milestone of fermentation and downstream process development in their development and manufacturing deal for RiVax, the former's ricin toxin vaccine....

CytRx arimoclomal Ph II trial placed on hold.(Brief Article)
August 1, 2005... Los Angeles, California, USA-based CytRx Corp says that, in response to an Investigational New Drug Application filed with the Food and Drug Administration for a planned Phase II clinical trial of arimoclomol for the treatment of amyotrophic...

VASTox commences SMA program.(Brief Article)
August 1, 2005... UK drug discovery and services group VASTox has initiated a new program which is focused on the discovery of therapies for spinal muscular atrophy, adding to its activities in Duchenne muscular dystrophy and tuberculosis. Commenting on the...

BioAlliance files IND for Ph III trial of Lauriad.(Investigational New Drug )(Brief Article)
August 1, 2005... France's BioAlliance Pharma has filed an Investigational New Drug application with the US Food and Drug Administration for a Phase III trial of its antifungal agent Lauriad (miconazole) for the treatment of oropharyngeal candidiasis. Chief...

Introgen's INGN 241 effective in cancer?(Brief Article)
August 1, 2005... Shares in US group Introgen Therapeutics climbed 3.1% to close at $6.60 following the July 21 news that recent data indicate that its INGN 241 induces the immune system to attack cancer cells via interleukin-24-dependent mechanisms. "These new...

Australian Rx numbers drop as prices rise.(Brief Article)
August 1, 2005... Following price rises for Pharmaceutical Benefits Scheme-subsidized drugs at the start of the year, Australian patients have cut their use dramatically, reports the Health Insurance Commission. 42.0 million prescriptions were filled in the...

Poor nations and "elite-only" access to ARVs.(antiretrovirals)
August 1, 2005... Impoverished nations which are being hit hard by HIV/AIDS should take steps to preserve their trained elites, within both their military and civilian sectors, through the provision of antiretroviral drugs, according to a new report published by...

Canadian provinces OK Genentech's Herceptin.(Brief Article)
August 1, 2005... In Canada, the provincial governments of Ontario, Quebec and Saskatchewan have announced that they will pay for Genentech's breakthrough therapy Herceptin (trastuzumab) for the treatment of early-stage breast cancer. After fast-tracking...

Tanzania: free ARVs.(Antiretrovirals)(Brief Article)
August 1, 2005... The government of Tanzania says it will supply 44,000 HIV/ AIDS patients with antiretroviral drugs by year-end. It currently provides the drugs free of charge to 21,000 patients, and raising the number 23,000 will cost an estimated $20.0...

EFPIA joins domestic and US drugmakers in urging Japan to adopt MRSP Rx pricing.(european Federation of Pharmaceutical Industries and Associations, manufacurer's suggested reimbursement price system)
August 1, 2005... The European Federation of Pharmaceutical Industries and Associations has urged Japan to adopt a manufacturer's suggested reimbursement price system as the new National Health Insurance drug price-setting mechanism. Similar proposals have...

Takeda R&D meeting focuses on insomnia treatment Rozeram.(research and development)
August 1, 2005... Japanese drug major Takeda presented its planned marketing strategies for Rozerem (ramelteon, TAK-375), an MT1/MT2 receptor agonist treatment for insomnia, at a recent R&D meeting with analysts. A New Drug Application was filed with US Food and...

Sanofi-Aventis: is growth slowing?(Brief Article)
August 1, 2005... The question being raised about the Franco-European drugmaker Sanofi-Aventis is whether its growth is beginning to slow down. Second-quarter 2005 sales in fact managed to expand at 10.1% compared with 7% for the pharmaceutical market as a whole...

Enbrel drives Wyeht's 2nd-qtr sales.(Brief Article)
August 1, 2005... Leading US health care group Wyeth has posted a strong set of second-quarter 2005 results, with turnover up 12% at $4.7 billion. Excluding favorable exchange rate impact, the rise was 10%. Net income and earnings per share both leapt 18% to...

Unfavorable pricing hits Mylan sales.(Brief Article)
August 1, 2005... US generics drugmaker Mylan Laboratories saw first-quarter fiscal 2005/6 (ended June 30) revenues dip 4.6% to $323.4 million. This was largely the result of overall unfavorable pricing but partially offset by new products. Gross profit for the...

Gilead's 2nd-qtr revenues up 55%.(Brief Article)
August 1, 2005... USA-based biotechnology company Gilead Sciences has reported record revenues for the second quarter of 2005, jumping 55% to $495.3 milliona and with HIV/ AIDS product sales leaping 61% to $344.4 million. Earnings per share rocketed 70% to...

CuraGen buys-back $39.9M of debt.(Brief Article)
August 1, 2005... Nasdaq-listed US firm CuraGen Corp says that, during July, it repurchased $25.9 million of face value of its 6% convertible subordinated notes due February 2007. The company also announced that in April and May it bought-back an additional...

ViroLogic's 2nd-qtr revenues leap 35%.(Brief Article)
August 1, 2005... US biopharmaceutical company ViroLogic has reported record turnover of $12.4 million for the second quarter of 2005, which was 35% higher than for the like, 2004 period. Driving the increase was revenue from the company's HIV...

Evotec in deal with P&G for discovery services.(Procter and Gamble Pharmaceuticals)(Brief Article)
August 1, 2005... Germany's Evotec AG and Procter & Gamble Pharmaceuticals say they have entered into agreements whereby the former will provide pharmaceutical discovery and chemical development services to P&GP. Under the terms of the accords, P&GP will...

Endo to submit response to Appeal Court over oxycodone.(Brief Article)
August 1, 2005... Endo Pharmaceuticals, a specialty US pharmaceutical company with market leadership in pain management, says that the US Federal Circuit Court of Appeals has requested the firm to submit a response brief as part of its review process of Purdue's...

Orphan status for UCB's brivaracetam in EU?(Brief Article)
August 1, 2005... Belgian group UCB says that the European Medicines Agency's Committee for Orphan Medicinal Products has recommended orphan medicinal product designation for its SV2A ligand brivaracetam (UCB 34714) for the treatment of progressive myoclonic...

Peregrine and US Army in antiviral testing deal.(Brief Article)
August 1, 2005... Peregrine Pharmaceuticals says it has signed a Cooperative R&D Agreement for Material Transfer with the US Army Medical Research Institute of Infectious Diseases to investigate the potential therapeutic application of the firm's anticancer drug...

Alnylam and Nastech sign RNAi accord.(RNA interference)(Brief Article)
August 1, 2005... RNA interference therapeutics group Alnylam Pharmaceuticals has granted fellow USA-based Nastech Pharmaceutical, which focuses on molecular biology-based drug delivery technologies, an exclusive license to InterfeRx for the discovery,...

MerLion and Merck & Co expand deal.(Brief Article)
August 1, 2005... Singapore-based MerLion Pharmaceuticals says it has expanded its existing collaboration with US drug major Merck & Co, which is centered on the discovery and development of new drug candidates derived from natural products chemistry. Under the...

Valeant to develop Viramidine in Japan.(Brief Article)
August 1, 2005... California, USA-based Valeant Pharmaceuticals International is planning to start the development of its nucleoside guanosine analog, Viramidine, in Japan, following the first meeting of its hepatitis C Japanese advisory board, held July 25 in...

Americans OK DTC ban on new drug launches.(direct-to-consumer advertising )
August 1, 2005... As US legislators and the pharmaceutical industry consider some form of moratorium on direct-to-consumer advertising for new prescription drugs for a time after their launch (see page 13 for the Pharmaceutical Research and Manufacturers of...

Rx info for patients "often confusing at best and dangerous at worst," says UK CSM report.(patient information leaflets)
August 1, 2005... The quantity of information about medicines made available to patients and carers is not in doubt but its quality very often has been, with results that are, at best, confusing and, at worst, downright dangerous, says the UK Committee on Safety...

New French drug ban targets antibiotics.(Brief Article)
August 1, 2005... 12 familiar medicines, sold in France for some time to treat throat conditions, are to be removed from the market from September 20, the health products safety agency, the Afssaps, has announced. From that date, pharmacies will no longer be...

Teva to regain No 1 generics spot with $7.4 acquisition of IVAX.
August 1, 2005... Israel's Teva Pharmaceutical Industries has announced its largest-ever acquisition, with a $7.4 billion bid for US generics maker IVAX Corp. The deal will put Teva back into the number one position in the global generics market, which it lost...

UPDATE: MGI Pharma makes $178M bid for Guilford, plus assuming $69.4M convertible debt.(Brief Article)
August 1, 2005... Further consolidation of US mid-sized drug companies is forthcoming, with the proposed acquisition of Guilford Pharmaceuticals by MGI Pharma. The latter has made a cash and stock offer of $178.0 million and will assume $69.4 million of...

S-P buys exclusive US rights to Integrilin.(Schering-Plough Corp.)(Brief Article)
August 1, 2005... US drug major Schering-Plough has reached agreement to acquire exclusive US marketing rights to Integrilin (eptifibatide) from partner Millennium Pharmaceuticals, with the aim of optimizing the growth potential of this US market-leading GP...

Genentech warns on Raptiva risk.(Brief Article)
August 1, 2005... US biotechnology firm Genentech, which is majority-owned by Swiss drugmaker Roche, has issued new safety information relating to Raptiva (efalizumab), which is indicated for the treatment of adults (18 years or older) with chronic...

FDA advisory on mifepristone.( US Food and Drug Administration)(Brief Article)
August 1, 2005... The US Food and Drug Administration says it is investigating recently-reported serious adverse events associated with the morning-after, pregnancy-terminating agent mifepristone (trade name Mifeprex, also known as RU-486). As a result, the FDA...

Alpharma to change Kadian labeling.(Brief Article)
August 1, 2005... USA-based Alpharma says that approval of its painkiller Kadian (morphine sulfate) 200mg extended-release capsules may be delayed as a result of a communication from the US Food and Drug Administration. A letter from the FDA states: "in...

Japan stock market week to July 25.
August 1, 2005... Tokyo saw a virtually flat market in the week ended July 25. The Nikkei 225 inched up 0.03%, to close at the 11,700 level, while the Topix index edged down 0.3%. The market started the review week firmly but recorded a steep daily drop on July...

Hospira ships first order of ceftriaxone.(Brief Article)
August 1, 2005... US drugmaker Hospira says that it has shipped the first customer orders of its generic ceftriaxone for injection, its copy version of Roche's Rocephin, the world's leading injectable antibiotic, which posted sales of over $650.0 million in...

Xanodyne completes buy of aaiPharma products.(Brief Article)
August 1, 2005... Xanodyne Pharmaceuticals, a privately-held, specialty pharmaceutical company focusing on innovative products in the therapeutic areas of women's health and pain management, say that it has completed the transaction to acquire most of the assets...

J&J becomes "Official Partner" for 2008 and other Olympics.( Johnson & Johnson )(Brief Article)
August 1, 2005... US health care major Johnson & Johnson and its subsidiaries have made a multinational commitment to the Olympic Movement and have become an Official Partner of the Beijing 2008 Olympic and Paralympic Games in China. They will also be the...

Ark's Trinam completes first stage of Ph II study.(Brief Article)
August 1, 2005... UK-based Ark Therapeutics says that it has completed patient enrolment for the low-dose arm of its Phase II study of Trinam (EG004) and has received approval to move to a higher dose. Trinam is Ark's novel therapy to prevent blood vessels...

First patient dosed with KuDOS' oral cancer agent.(Brief Article)
August 1, 2005... KuDOS Pharmaceuticals, a UK drug development company that targets DNA damage sensing and signalling to improve the treatment of cancer, has announced that the first patient has been dosed in a Phase I clinical study of its oral PARP inhibitor...

AstraZeneca signs development/licensing deals with Schering AG and Astex.
August 1, 2005... Anglo-Swedish drugmaker AstraZeneca has announced two new discovery, development and commercialization agreements with European drugmakers which, if successful, will serve to breathe new life into the firm's pipeline, as well as potentially...

UCB's Ph III Cimzia trials meet endpoint.(crohn's disease)(Brief Article)
August 1, 2005... Belgium-based UCB has reported positive results from the Phase III trials PRECiSE 1 and 2, which assessed the ability of its Cimzia (certolizumab pegol) to induce and maintain a clinical response in moderate-to-severe active Crohn's disease....

Encouraging data for Immune Response 's IR103 and Remune.(Brief Article)
August 1, 2005... US biopharmaceutical group The Immune Response Corp saw its shares close up 14.5% at $0.79 on July 26, following presentations at the International AIDS Society meeting in Rio de Janeiro, Brazil, of the first clinical trial data for its...

Robust long-term safety data for GSK/Vertex' Lexiva.(Brief Article)
August 1, 2005... Data presented at the 3rd Annual International AIDS Society Conference in Rio de Janeiro, Brazil, showed that HIV patients with hepatitis C or B experienced no negative effect to liver enzymes from 120 weeks of therapy with a once-daily dose of...

Adventrx unveils positive data for Thiovir at IAS 2005.(Brief Article)
August 1, 2005... US group Adventrx has presented encouraging results from an in vitro study of its nucleoside reverse transcriptase inhibitor Thiovir at the International AIDS Society meeting in Rio de Janeiro, Brazil. Data from the trial showed that Thiovir...

Newest HIV drugs should be given with Fuzeon, data indicates.(research)(Brief Article)
August 1, 2005... Results unveiled at the International AIDS Society Conference in Rio de Janeiro, Brazil, support mounting evidence which suggests that Swiss drugmaker Roche and US group Trimeris' Fuzeon (enfuvirtide) should be combined with the newest drugs to...

India set for solid growth in pharmaceutical industry, says new PwC report.
August 1, 2005... The economy of India is expanding rapidly along with its population, giving rise to a growing number of middle class citizens with enough funds to buy medicines from western drugmakers, notes a recent PricewaterhouseCoopers report, entitled...

UK pharma/NHS joint-working guide revised.(Association of the British Pharmaceutical Industry.)(National Health Service of United Kingdom.)
August 1, 2005... Ways in which the pharmaceutical industry can work in cooperation with the UK National Health Service are outlined in a revised framework which has been agreed between the National Association of Primary Care, the NHS Alliance, the NHS...

French agree to limit pharma rep visits.(Brief Article)
August 1, 2005... An agreement to limit the frequency of visits to doctors by representatives of pharmaceutical manufacturers in France has been reached between the LEEM drug industry association and the Economic Committee on Healthcare Products, the CEPS. ...

Russia: new pharma import rules.(Brief Article)
August 1, 2005... Russia's government has approved new regulations permitting pharmaceuticals to be imported into the country by their manufacturers, wholesalers and scientific research institutes only, and for the Federal Supervisory Service for Health and...

US prices for new HIV/AIDS drugs are "unreasonable, unacceptable, unjustified".
August 1, 2005... Pharmaceutical manufacturers in the USA are artificially inflating the market at the expense of people living with HIV/AIDS, claims the AIDS Treatment Activists Coalition. As an example, the group points to Boehringer Ingelheim's...